ClinicalTrials.gg
CompletedNCT03548584Updated Sep 18, 2023Results posted

A Trial to Evaluate the Safety, Efficacy, and Tolerability of Brexpiprazole in Treating Agitation Associated With Dementia of the Alzheimer's Type

A Phase 3 interventional study of Brexpiprazole and Placebo in Agitation Associated With Alzheimer's Dementia and Alzheimer Dementia, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 1 site in United States. Open to participants aged 55 Years to 90 Years. Per ClinicalTrials.gov, last updated 2023-09-18.

Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
345
Allocation
Randomized
Ages
55 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies in Alzheimer Disease by Otsuka Holdings Co., Ltd. — 1 open to participants now, 1 under way, none of them phase 3. Alzheimer Disease · Otsuka Holdings Co., Ltd..

Enrollment
5th of 12
345 · median 265
Started
2018
with 1 other
Phase 3
13 of 17
none open now
Registered
13th of 17
by date

Among the 17 studies in Alzheimer Disease by Otsuka Holdings Co., Ltd., this one is the 5th largest by enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2018, is one of 13 in phase 3, and was the 13th registered.

Alzheimer Disease

3,972 studies on the registry are indexed under Alzheimer Disease; 932 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

1 of the 17 studies in Alzheimer Disease by Otsuka Holdings Co., Ltd. is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.

This study: 55 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Alzheimer Disease by Otsuka Holdings Co., Ltd., or all of them as a file.
02

Study summary

This study compares the efficacy of 2 doses of brexpiprazole with placebo in participants with agitation associated with dementia of the Alzheimer's type.

Read the detailed description

This is a phase 3, 12-week, multicenter, randomized, double-blind, placebo-controlled, fixed-dose trial designed to assess the efficacy, safety, and tolerability of brexpiprazole compared with placebo. The trial consists of a 12-week double-blind treatment period with a 30 day follow-up. The trial population will include male and female participants between 55 and 90 years of age (inclusive) with a diagnosis of probable Alzheimer's disease, who are residing either in an institutionalized setting or in a non-institutionalized setting where the participant is not living alone. This trial will analyze data gathered from approximately 330 participants at multiple countries. Participants may also be eligible to enter an active treatment extension trial.

03

Conditions studied

  • Agitation Associated With Alzheimer's Dementia
  • Alzheimer Dementia

Keywords

  • Agitation
04

Who can participate

Ages eligible
55 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants with a diagnosis of probable Alzheimer's disease.
  • Participants with a diagnosis of agitation
  • Participants with a score of 5 to 22, inclusive, at screening and baseline visits.
  • Participants with a previous MRI or CT scan of the brain, that was performed after the onset of symptoms of dementia, with findings consistent with a diagnosis of Alzheimer's disease.
  • Participants who are residing at their current location for at least 28 days before screening and are expected to remain at the same location for the duration of the trial.
  • Institutionalized participants with an identified caregiver who has sufficient contact (minimum of 2 hours per day for 4 days per week) to describe the participant's symptoms and has direct observation of the participant's behavior. Non-institutionalized participants may not be living alone and must have an identified caregiver who has sufficient contact (minimum of 2 hours per day for 4 days per week) to describe the participant's symptoms and has direct observation of the participant's behavior.
  • Participants with onset of symptoms of agitation at least 2 weeks prior to screening visit.
  • Participants will and able to discontinue all prohibited concomitant medications to meet protocol required washouts prior to and during the trial period.

Exclusion criteria

Exclusion Criteria:

  • Participants with dementia or other memory impairment not due to Alzheimer's disease.
  • Participants with a history of stroke, well-documented , or pulmonary or cerebral embolism.
  • Participants who had an insufficient response, based on the investigator's judgment, to 2 or more previous antipsychotic medications.
  • Participants who have been diagnosed with an Axis I disorder.
  • Participants who currently have neurological, hepatic, renal, metabolic, hematological, immunological, cardiovascular, pulmonary, gastrointestinal, or psychiatric disorders.
  • Participants with uncontrolled hypertension or symptomatic hypotension, or orthostatic hypotension.
  • Participants with diabetes mellitus (insulin-dependent and non-insulin-dependent) may be eligible for the trial if their condition is stable and well-controlled.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
345 participants (actual)

Study arms

  • Experimental
    Brexpiprazole 2 mg

    Participants followed a titration schedule, to gradually increase their dose from 0.5 milligrams per day (mg/day) in the starting to 2 mg/day from Day 15. Participants continued to receive brexpiprazole 2 milligrams (mg), once daily until Week 12.

    Drug: Brexpiprazole

  • Experimental
    Brexpiprazole 3 mg

    Participants followed a titration schedule, to gradually increase their dose from 0.5 mg/day in the starting to 3 mg/day from Day 29. Participants continued to receive brexpiprazole 3 mg, once daily until Week 12.

    Drug: Brexpiprazole

  • Placebo comparator
    Placebo

    Participants received matching placebo, once daily for 12 weeks.

    Other: Placebo

Interventions

  • Oral tablets

    Also known as: OPC-34712

  • OtherPlacebo

    Oral tablets

06

What researchers measure

Primary outcomes

  1. Change From Baseline to Week 12 in the CMAI Total Score

    The CMAI score is used to assess the frequency of manifestations of agitated behaviors in participants. The CMAI consists of 29 agitated behaviors that are rated on a 7-point scale of frequency across four subscales of aggressive behavior, physically nonaggressive behavior, verbally agitated behavior and hiding and hoarding as: 1=never; 2=less than once a week; 3=once or twice a week; 4=several times a week; 5=once or twice a day; 6=several times a day; 7=several times an hour. The CMAI total score ranges from 29 to 203. Higher scores indicate worsening of the condition. A negative change from baseline indicates improvement. Mixed model repeated measures (MMRM) was used for the analysis. As prespecified in the statistical analysis plan (SAP), data for this outcome measure was analyzed and reported in a combined way for brexpiprazole 2 and 3 mg.

    Time frame: Baseline and Week 12

Secondary outcomes

  1. Change From Baseline to Week 12 in the Clinical Global Impression Severity of Illness (CGI-S) Score, as Related to Agitation

    CGI-S was used to rate the severity of agitation. The score ranges from 0 to 7 with response choices as, 0=not assessed; 1=normal, not at all ill; 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; and 7=among the most extremely ill participants. The higher the value, the more severe the agitation. A negative change from baseline indicates improvement. MMRM was used for the analysis. As prespecified in the SAP, data for this outcome measure was analyzed and reported in a combined way for brexpiprazole 2 and 3 mg.

    Time frame: Baseline and Week 12

  2. Change From Baseline to Week 12 in CMAI Subscale Scores

    The CMAI score is used to assess the frequency of manifestations of agitated behaviors in participants. It consists of 29 agitated behaviors that are rated on a 7-point scale of frequency across four subscales of aggressive behavior, physically nonaggressive behavior, verbally agitated behavior and hiding and hoarding, as: 1=never; 2=less than once a week; 3=once or twice a week; 4=several times a week; 5=once or twice a day; 6=several times a day; 7=several times an hour. The four subscales include 12, 6, 4, and 2 items, respectively. The score of the subscale is the sum of the individual items included in the subscale, so the score range for each of the 4 subscales is 0 to 84, 0 to 42, 0 to 28, and 0 to 14, respectively. Higher scores indicate worsening of the condition. A negative change from baseline=improvement. MMRM was used for the analysis. As prespecified in the SAP, data for this outcome measure was analyzed and reported in a combined way for brexpiprazole 2 and 3 mg.

    Time frame: Baseline and Week 12

  3. Change From Baseline in CMAI Total Score for Each Trial Visit During the Double-blind Treatment Period

    The CMAI score is used to assess the frequency of manifestations of agitated behaviors in participants. The CMAI consists of 29 agitated behaviors that are rated on a 7-point scale of frequency across four subscales of aggressive behavior, physically nonaggressive behavior, verbally agitated behavior and hiding and hoarding as: 1=never; 2=less than once a week; 3=once or twice a week; 4=several times a week; 5=once or twice a day; 6=several times a day; 7=several times an hour. The CMAI total score ranges from 29 to 203. Higher scores indicate worsening of the condition. A negative change from baseline indicates improvement. MMRM was used for the analysis. As prespecified in the SAP, data for this outcome measure was analyzed and reported in a combined way for brexpiprazole 2 and 3 mg.

    Time frame: Baseline, Weeks 2, 4, 6, 8, 10, and 12

  4. Change From Baseline in CGI-S for Each Trial Visit During the Double-Blind Treatment Period

    CGI-S was used to rate the severity of agitation. The score ranges from 0 to 7 with response choices as, 0=not assessed; 1=normal, not at all ill; 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; and 7=among the most extremely ill participants. The higher the value, the more severe the agitation. A negative change from baseline indicates improvement. MMRM was used for the analysis. As prespecified in the SAP, data for this outcome measure was analyzed and reported in a combined way for brexpiprazole 2 and 3 mg.

    Time frame: Baseline, Weeks 2, 4, 6, 8, 10, and 12

  5. Clinical Global Impressions-Improvement (CGI-I) Score at Each Trial Visit During the Double-Blind Treatment Period

    CGI-I is a 7-point scale that requires the clinician to assess whether a participant's condition has improved or worsened relative to a baseline state at the beginning of the intervention. This was rated as: 1=very much improved; 2=much improved; 3=minimally improved; 4=no change; 5=minimally worse; 6=much worse; or 7=very much worse. Higher scores indicate worse condition. As prespecified in the SAP, data for this outcome measure was analyzed and reported in a combined way for brexpiprazole 2 and 3 mg.

    Time frame: Baseline, Weeks 2, 4, 6, 8, 10, and 12

  6. CMAI Response Rate Assessed as Percentage of Participants With CMAI Response at Every Scheduled Trial Visit in the Double-Blind Treatment Period

    The CMAI assesses frequency of agitated behaviors in elderly persons. The scale consists of 29 agitated behaviors that are further categorized into distinct agitation syndromes, also known as CMAI factors of agitation. Each of the agitated behaviors are scored 1 (never) to 7 (several times an hours), with the total scale score ranging from 29 to 203. Higher score indicates greater frequency of agitated behavior. As prespecified in the SAP, data for this outcome measure was analyzed and reported in a combined way for brexpiprazole 2 and 3 mg.

    Time frame: Weeks 2, 4, 6, 8, 10, and 12

  7. CMAI Response Rate Assessed as Percentage of Participants With CMAI Response Based on Improvement From Baseline in Agitation Status at Every Scheduled Trial Visit in the Double-Blind Treatment Period

    The CMAI assesses frequency of agitated behaviors in elderly persons. The scale consists of 29 agitated behaviors that are further categorized into distinct agitation syndromes, also known as CMAI factors of agitation. Each of the agitated behaviors are scored 1 (never) to 7 (several times an hours), with the total scale score ranging from 29 to 203. Higher score indicates greater frequency of agitated behavior. As prespecified in the SAP, data for this outcome measure was analyzed and reported in a combined way for brexpiprazole 2 and 3 mg.

    Time frame: Baseline, Weeks 2, 4, 6, 8, 10, and 12

  8. CGI-I Response Rate Assessed as Percentage of Participants With CGI-I Response at Every Scheduled Trial Visit in the Double-Blind Treatment Period

    CGI-I is a 7-point scale that requires the clinician to assess whether a participant's condition has improved or worsened relative to a baseline state at the beginning of the intervention. This was rated as: 1=very much improved; 2=much improved; 3=minimally improved; 4=no change; 5=minimally worse; 6=much worse; or 7=very much worse. Higher scores indicate worse condition. As prespecified in the SAP, data for this outcome measure was analyzed and reported in a combined way for brexpiprazole 2 and 3 mg.

    Time frame: Baseline, Weeks 2, 4, 6, 8, 10, and 12

07

Results

Posted Sep 18, 2023

Participant flow

A total of 345 participants were randomized, and participated in the study from 16 May 2018 to 1 June 2022.

Participant flow — Overall Study
MilestoneBrexpiprazole 2 mgBrexpiprazole 3 mgPlacebo
Started75153117
Intent-to-treat population73153116
Completed68130104
Not completed72313
Withdrew: Lost to follow-up001
Withdrew: Adverse event1115
Withdrew: Site terminated by sponsor132
Withdrew: Subject withdrew consent to participate553
Withdrew: Lack of efficacy010
Withdrew: Non-compliance with study drug010
Withdrew: Reason not specified (not related to coronavirus disease 2019 [covid-19])022

Outcome measures

PrimaryChange From Baseline to Week 12 in the CMAI Total Score

The CMAI score is used to assess the frequency of manifestations of agitated behaviors in participants. The CMAI consists of 29 agitated behaviors that are rated on a 7-point scale of frequency across four subscales of aggressive behavior, physically nonaggressive behavior, verbally agitated behavior and hiding and hoarding as: 1=never; 2=less than once a week; 3=once or twice a week; 4=several times a week; 5=once or twice a day; 6=several times a day; 7=several times an hour. The CMAI total score ranges from 29 to 203. Higher scores indicate worsening of the condition. A negative change from baseline indicates improvement. Mixed model repeated measures (MMRM) was used for the analysis. As prespecified in the statistical analysis plan (SAP), data for this outcome measure was analyzed and reported in a combined way for brexpiprazole 2 and 3 mg.

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · score on a scale
Change From Baseline to Week 12 in the CMAI Total Score
score on a scaleBrexpiprazole 2 and 3 mgPlacebo
Change From Baseline to Week 12 in the CMAI Total Score-22.6 ± 1.08-17.3 ± 1.44
Statistical analysis
  • Brexpiprazole 2 and 3 mg vs Placebo · MMRM · p = 0.0026 (MMRM method with model terms of treatment, trial site, visit, treatment-by-visit and baseline-by-visit interaction were used for analysis.) · Ls mean difference: -5.32 · 95% CI -8.77 to -1.87
SecondaryChange From Baseline to Week 12 in the Clinical Global Impression Severity of Illness (CGI-S) Score, as Related to Agitation

CGI-S was used to rate the severity of agitation. The score ranges from 0 to 7 with response choices as, 0=not assessed; 1=normal, not at all ill; 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; and 7=among the most extremely ill participants. The higher the value, the more severe the agitation. A negative change from baseline indicates improvement. MMRM was used for the analysis. As prespecified in the SAP, data for this outcome measure was analyzed and reported in a combined way for brexpiprazole 2 and 3 mg.

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · score on a scale
Change From Baseline to Week 12 in the Clinical Global Impression Severity of Illness (CGI-S) Score, as Related to Agitation
score on a scaleBrexpiprazole 2 and 3 mgPlacebo
Change From Baseline to Week 12 in the Clinical Global Impression Severity of Illness (CGI-S) Score, as Related to Agitation-1.20 ± 0.06-0.93 ± 0.08
Statistical analysis
  • Brexpiprazole 2 and 3 mg vs Placebo · MMRM · p = 0.0078 (MMRM method with model terms of treatment, trial site, visit, treatment-by-visit and baseline-by-visit interaction were used for analysis.) · Ls mean difference: -0.27 · 95% CI -0.47 to -0.07
SecondaryChange From Baseline to Week 12 in CMAI Subscale Scores

The CMAI score is used to assess the frequency of manifestations of agitated behaviors in participants. It consists of 29 agitated behaviors that are rated on a 7-point scale of frequency across four subscales of aggressive behavior, physically nonaggressive behavior, verbally agitated behavior and hiding and hoarding, as: 1=never; 2=less than once a week; 3=once or twice a week; 4=several times a week; 5=once or twice a day; 6=several times a day; 7=several times an hour. The four subscales include 12, 6, 4, and 2 items, respectively. The score of the subscale is the sum of the individual items included in the subscale, so the score range for each of the 4 subscales is 0 to 84, 0 to 42, 0 to 28, and 0 to 14, respectively. Higher scores indicate worsening of the condition. A negative change from baseline=improvement. MMRM was used for the analysis. As prespecified in the SAP, data for this outcome measure was analyzed and reported in a combined way for brexpiprazole 2 and 3 mg.

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · score on a scale
Change From Baseline to Week 12 in CMAI Subscale Scores
score on a scaleBrexpiprazole 2 and 3 mgPlacebo
Aggressive Behavior-9.09 ± 0.42-7.13 ± 0.56
Physically Nonaggressive Behavior-6.45 ± 0.40-5.04 ± 0.53
Verbally Agitated Behavior-4.39 ± 0.31-3.14 ± 0.40
Hiding and Hoarding-1.50 ± 0.17-1.14 ± 0.23
Statistical analysis
  • Brexpiprazole 2 and 3 mg vs Placebo · MMRM · p = 0.0040 (MMRM method with model terms of treatment, trial site, visit, treatment-by-visit and baseline-by-visit interaction were used for analysis.) · Ls mean difference: -1.95 · 95% CI -3.28 to -0.63
  • Brexpiprazole 2 and 3 mg vs Placebo · MMRM · p = 0.0296 (MMRM method with model terms of treatment, trial site, visit, treatment-by-visit and baseline-by-visit interaction were used for analysis.) · Ls mean difference: -1.41 · 95% CI -2.68 to -0.14
  • Brexpiprazole 2 and 3 mg vs Placebo · MMRM · p = 0.0113 (MMRM method with model terms of treatment, trial site, visit, treatment-by-visit and baseline-by-visit interaction were used for analysis.) · Ls mean difference: -1.24 · 95% CI -2.21 to -0.28
  • Brexpiprazole 2 and 3 mg vs Placebo · MMRM · p = 0.1941 (MMRM method with model terms of treatment, trial site, visit, treatment-by-visit and baseline-by-visit interaction were used for analysis.) · Ls mean difference: -0.36 · 95% CI -0.90 to 0.18
SecondaryChange From Baseline in CMAI Total Score for Each Trial Visit During the Double-blind Treatment Period

The CMAI score is used to assess the frequency of manifestations of agitated behaviors in participants. The CMAI consists of 29 agitated behaviors that are rated on a 7-point scale of frequency across four subscales of aggressive behavior, physically nonaggressive behavior, verbally agitated behavior and hiding and hoarding as: 1=never; 2=less than once a week; 3=once or twice a week; 4=several times a week; 5=once or twice a day; 6=several times a day; 7=several times an hour. The CMAI total score ranges from 29 to 203. Higher scores indicate worsening of the condition. A negative change from baseline indicates improvement. MMRM was used for the analysis. As prespecified in the SAP, data for this outcome measure was analyzed and reported in a combined way for brexpiprazole 2 and 3 mg.

Time frame:
Baseline, Weeks 2, 4, 6, 8, 10, and 12
Reported as:
Least squares mean · score on a scale
Change From Baseline in CMAI Total Score for Each Trial Visit During the Double-blind Treatment Period
score on a scaleBrexpiprazole 2 and 3 mgPlacebo
Change From Baseline at Week 2-5.76 ± 0.71-6.61 ± 0.90
Change From Baseline at Week 4-12.1 ± 0.82-11.0 ± 1.06
Change From Baseline at Week 6-16.2 ± 0.91-13.9 ± 1.19
Change From Baseline at Week 8-19.4 ± 0.96-14.4 ± 1.28
Change From Baseline at Week 10-22.2 ± 0.97-15.7 ± 1.29
Change From Baseline at Week 12-22.6 ± 1.08-17.3 ± 1.44
Statistical analysis
  • Brexpiprazole 2 and 3 mg vs Placebo · MMRM · p = 0.4242 (MMRM method with model terms of treatment, trial site, visit, treatment-by-visit and baseline-by-visit interaction were used for analysis.) · Ls mean difference: 0.85 · 95% CI -1.24 to 2.93
  • Brexpiprazole 2 and 3 mg vs Placebo · MMRM · p = 0.3665 (MMRM method with model terms of treatment, trial site, visit, treatment-by-visit and baseline-by-visit interaction were used for analysis.) · Ls mean difference: -1.14 · 95% CI -3.63 to 1.34
  • Brexpiprazole 2 and 3 mg vs Placebo · MMRM · p = 0.1065 (MMRM method with model terms of treatment, trial site, visit, treatment-by-visit and baseline-by-visit interaction were used for analysis.) · Ls mean difference: -2.32 · 95% CI -5.15 to 0.50
  • Brexpiprazole 2 and 3 mg vs Placebo · MMRM · p = 0.0011 (MMRM method with model terms of treatment, trial site, visit, treatment-by-visit and baseline-by-visit interaction were used for analysis.) · Ls mean difference: -5.08 · 95% CI -8.12 to -2.05
  • Brexpiprazole 2 and 3 mg vs Placebo · MMRM · p = <.0001 (MMRM method with model terms of treatment, trial site, visit, treatment-by-visit and baseline-by-visit interaction were used for analysis.) · Ls mean difference: -6.47 · 95% CI -9.54 to -3.40
  • Brexpiprazole 2 and 3 mg vs Placebo · MMRM · p = 0.0026 (MMRM method with model terms of treatment, trial site, visit, treatment-by-visit and baseline-by-visit interaction were used for analysis.) · Ls mean difference: -5.32 · 95% CI -8.77 to -1.87
SecondaryChange From Baseline in CGI-S for Each Trial Visit During the Double-Blind Treatment Period

CGI-S was used to rate the severity of agitation. The score ranges from 0 to 7 with response choices as, 0=not assessed; 1=normal, not at all ill; 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; and 7=among the most extremely ill participants. The higher the value, the more severe the agitation. A negative change from baseline indicates improvement. MMRM was used for the analysis. As prespecified in the SAP, data for this outcome measure was analyzed and reported in a combined way for brexpiprazole 2 and 3 mg.

Time frame:
Baseline, Weeks 2, 4, 6, 8, 10, and 12
Reported as:
Least squares mean · score on a scale
Change From Baseline in CGI-S for Each Trial Visit During the Double-Blind Treatment Period
score on a scaleBrexpiprazole 2 and 3 mgPlacebo
Change From Baseline at Week 2-0.21 ± 0.03-0.27 ± 0.04
Change From Baseline at Week 4-0.53 ± 0.05-0.50 ± 0.06
Change From Baseline at Week 6-0.74 ± 0.05-0.68 ± 0.07
Change From Baseline at Week 8-0.97 ± 0.06-0.70 ± 0.08
Change From Baseline at Week 10-1.14 ± 0.06-0.86 ± 0.08
Change From Baseline at Week 12-1.20 ± 0.06-0.93 ± 0.08
Statistical analysis
  • Brexpiprazole 2 and 3 mg vs Placebo · MMRM · p = 0.3048 (MMRM method with model terms of treatment, trial site, visit, treatment-by-visit and baseline-by-visit interaction were used for analysis.) · Ls mean difference: 0.05 · 95% CI -0.05 to 0.16
  • Brexpiprazole 2 and 3 mg vs Placebo · MMRM · p = 0.7058 (MMRM method with model terms of treatment, trial site, visit, treatment-by-visit and baseline-by-visit interaction were used for analysis.) · Ls mean difference: -0.03 · 95% CI -0.17 to 0.12
  • Brexpiprazole 2 and 3 mg vs Placebo · MMRM · p = 0.4516 (MMRM method with model terms of treatment, trial site, visit, treatment-by-visit and baseline-by-visit interaction were used for analysis.) · Ls mean difference: -0.06 · 95% CI -0.23 to 0.10
  • Brexpiprazole 2 and 3 mg vs Placebo · MMRM · p = 0.0052 (MMRM method with model terms of treatment, trial site, visit, treatment-by-visit and baseline-by-visit interaction were used for analysis.) · Ls mean difference: -0.27 · 95% CI -0.46 to -0.08
  • Brexpiprazole 2 and 3 mg vs Placebo · MMRM · p = 0.0060 (MMRM method with model terms of treatment, trial site, visit, treatment-by-visit and baseline-by-visit interaction were used for analysis.) · Ls mean difference: -0.27 · 95% CI -0.47 to -0.08
  • Brexpiprazole 2 and 3 mg vs Placebo · MMRM · p = 0.0078 (MMRM method with model terms of treatment, trial site, visit, treatment-by-visit and baseline-by-visit interaction were used for analysis.) · Ls mean difference: -0.27 · 95% CI -0.47 to -0.07
SecondaryClinical Global Impressions-Improvement (CGI-I) Score at Each Trial Visit During the Double-Blind Treatment Period

CGI-I is a 7-point scale that requires the clinician to assess whether a participant's condition has improved or worsened relative to a baseline state at the beginning of the intervention. This was rated as: 1=very much improved; 2=much improved; 3=minimally improved; 4=no change; 5=minimally worse; 6=much worse; or 7=very much worse. Higher scores indicate worse condition. As prespecified in the SAP, data for this outcome measure was analyzed and reported in a combined way for brexpiprazole 2 and 3 mg.

Time frame:
Baseline, Weeks 2, 4, 6, 8, 10, and 12
Reported as:
Mean · score on a scale
Clinical Global Impressions-Improvement (CGI-I) Score at Each Trial Visit During the Double-Blind Treatment Period
score on a scaleBrexpiprazole 2 and 3 mgPlacebo
Week 23.70 ± 0.753.57 ± 0.69
Week 43.19 ± 0.853.39 ± 0.87
Week 62.92 ± 0.943.19 ± 0.95
Week 82.80 ± 1.003.16 ± 1.01
Week 102.62 ± 0.992.97 ± 1.00
Week 122.66 ± 1.092.97 ± 1.12
Statistical analysis
  • Brexpiprazole 2 and 3 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.1975 · Mean difference (final values): 0.10 · 95% CI -0.05 to 0.26
  • Brexpiprazole 2 and 3 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.0084 · Mean difference (final values): -0.25 · 95% CI -0.44 to -0.06
  • Brexpiprazole 2 and 3 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.0101 · Mean difference (final values): -0.26 · 95% CI -0.46 to -0.06
  • Brexpiprazole 2 and 3 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.0008 · Mean difference (final values): -0.37 · 95% CI -0.59 to -0.15
  • Brexpiprazole 2 and 3 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.0023 · Mean difference (final values): -0.34 · 95% CI -0.55 to -0.12
  • Brexpiprazole 2 and 3 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.0070 · Mean difference (final values): -0.33 · 95% CI -0.57 to -0.09
SecondaryCMAI Response Rate Assessed as Percentage of Participants With CMAI Response at Every Scheduled Trial Visit in the Double-Blind Treatment Period

The CMAI assesses frequency of agitated behaviors in elderly persons. The scale consists of 29 agitated behaviors that are further categorized into distinct agitation syndromes, also known as CMAI factors of agitation. Each of the agitated behaviors are scored 1 (never) to 7 (several times an hours), with the total scale score ranging from 29 to 203. Higher score indicates greater frequency of agitated behavior. As prespecified in the SAP, data for this outcome measure was analyzed and reported in a combined way for brexpiprazole 2 and 3 mg.

Time frame:
Weeks 2, 4, 6, 8, 10, and 12
Reported as:
Number · percentage of participants
CMAI Response Rate Assessed as Percentage of Participants With CMAI Response at Every Scheduled Trial Visit in the Double-Blind Treatment Period
percentage of participantsBrexpiprazole 2 and 3 mgPlacebo
>/= 20%: Week 211.313.2
>/= 20%: Week 429.327.6
>/= 20%: Week 643.137.9
>/= 20%: Week 859.638.8
>/= 20%: Week 1065.845.7
>/= 20%: Week 1268.447.4
>/= 30%: Week 23.623.51
>/= 30%: Week 410.710.3
>/= 30%: Week 622.720.7
>/= 30%: Week 832.919.0
>/= 30%: Week 1038.224.1
>/= 30%: Week 1242.725.9
>/= 40%: Week 21.811.75
>/= 40%: Week 44.895.17
>/= 40%: Week 610.78.62
>/= 40%: Week 816.98.62
>/= 40%: Week 1020.911.2
>/= 40%: Week 1223.114.7
Statistical analysis
  • Brexpiprazole 2 and 3 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.7290 · Ratio of response rate: 1.10 · 95% CI 0.64 to 1.91
  • Brexpiprazole 2 and 3 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.6196 · Ratio of response rate: 1.09 · 95% CI 0.78 to 1.52
  • Brexpiprazole 2 and 3 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.2718 · Ratio of response rate: 1.16 · 95% CI 0.88 to 1.53
  • Brexpiprazole 2 and 3 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.0004 · Ratio of response rate: 1.52 · 95% CI 1.19 to 1.93
  • Brexpiprazole 2 and 3 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.0006 · Ratio of response rate: 1.42 · 95% CI 1.15 to 1.76
  • Brexpiprazole 2 and 3 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.0004 · Ratio of response rate: 1.41 · 95% CI 1.15 to 1.72
  • Brexpiprazole 2 and 3 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.7211 · Ratio of response rate: 1.22 · 95% CI 0.39 to 3.85
  • Brexpiprazole 2 and 3 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.7606 · Ratio of response rate: 1.11 · 95% CI 0.57 to 2.14
  • Brexpiprazole 2 and 3 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.5902 · Ratio of response rate: 1.12 · 95% CI 0.74 to 1.68
  • Brexpiprazole 2 and 3 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.0054 · Ratio of response rate: 1.70 · 95% CI 1.14 to 2.54
  • Brexpiprazole 2 and 3 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.0066 · Ratio of response rate: 1.59 · 95% CI 1.11 to 2.26
  • Brexpiprazole 2 and 3 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.0017 · Ratio of response rate: 1.62 · 95% CI 1.18 to 2.23
  • Brexpiprazole 2 and 3 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.9074 · Ratio of response rate: 1.11 · 95% CI 0.20 to 5.97
  • Brexpiprazole 2 and 3 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.9625 · Ratio of response rate: 0.98 · 95% CI 0.36 to 2.64
  • Brexpiprazole 2 and 3 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.5120 · Ratio of response rate: 1.26 · 95% CI 0.63 to 2.53
  • Brexpiprazole 2 and 3 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.0244 · Ratio of response rate: 1.98 · 95% CI 1.03 to 3.79
  • Brexpiprazole 2 and 3 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.0161 · Ratio of response rate: 1.86 · 95% CI 1.08 to 3.18
  • Brexpiprazole 2 and 3 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.0347 · Ratio of response rate: 1.62 · 95% CI 1.00 to 2.61
SecondaryCMAI Response Rate Assessed as Percentage of Participants With CMAI Response Based on Improvement From Baseline in Agitation Status at Every Scheduled Trial Visit in the Double-Blind Treatment Period

The CMAI assesses frequency of agitated behaviors in elderly persons. The scale consists of 29 agitated behaviors that are further categorized into distinct agitation syndromes, also known as CMAI factors of agitation. Each of the agitated behaviors are scored 1 (never) to 7 (several times an hours), with the total scale score ranging from 29 to 203. Higher score indicates greater frequency of agitated behavior. As prespecified in the SAP, data for this outcome measure was analyzed and reported in a combined way for brexpiprazole 2 and 3 mg.

Time frame:
Baseline, Weeks 2, 4, 6, 8, 10, and 12
Reported as:
Number · percentage of participants
CMAI Response Rate Assessed as Percentage of Participants With CMAI Response Based on Improvement From Baseline in Agitation Status at Every Scheduled Trial Visit in the Double-Blind Treatment Period
percentage of participantsBrexpiprazole 2 and 3 mgPlacebo
Week 28.1414.0
Week 420.419.0
Week 633.826.7
Week 844.031.0
Week 1050.234.5
Week 1252.437.1
Statistical analysis
  • Brexpiprazole 2 and 3 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.1503 · Ratio of response rate: 0.64 · 95% CI 0.35 to 1.16
  • Brexpiprazole 2 and 3 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.7559 · Ratio of response rate: 1.07 · 95% CI 0.69 to 1.67
  • Brexpiprazole 2 and 3 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.2246 · Ratio of response rate: 1.23 · 95% CI 0.88 to 1.72
  • Brexpiprazole 2 and 3 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.0276 · Ratio of response rate: 1.38 · 95% CI 1.02 to 1.87
  • Brexpiprazole 2 and 3 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.0031 · Ratio of response rate: 1.46 · 95% CI 1.12 to 1.89
  • Brexpiprazole 2 and 3 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.0017 · Ratio of response rate: 1.47 · 95% CI 1.14 to 1.89
SecondaryCGI-I Response Rate Assessed as Percentage of Participants With CGI-I Response at Every Scheduled Trial Visit in the Double-Blind Treatment Period

CGI-I is a 7-point scale that requires the clinician to assess whether a participant's condition has improved or worsened relative to a baseline state at the beginning of the intervention. This was rated as: 1=very much improved; 2=much improved; 3=minimally improved; 4=no change; 5=minimally worse; 6=much worse; or 7=very much worse. Higher scores indicate worse condition. As prespecified in the SAP, data for this outcome measure was analyzed and reported in a combined way for brexpiprazole 2 and 3 mg.

Time frame:
Baseline, Weeks 2, 4, 6, 8, 10, and 12
Reported as:
Number · percentage of participants
CGI-I Response Rate Assessed as Percentage of Participants With CGI-I Response at Every Scheduled Trial Visit in the Double-Blind Treatment Period
percentage of participantsBrexpiprazole 2 and 3 mgPlacebo
Week 24.985.26
Week 421.812.1
Week 635.123.3
Week 844.424.1
Week 1052.433.6
Week 1252.440.5
Statistical analysis
  • Brexpiprazole 2 and 3 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.8549 · Ratio of response rate: 1.10 · 95% CI 0.40 to 3.03
  • Brexpiprazole 2 and 3 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.0093 · Ratio of response rate: 1.95 · 95% CI 1.14 to 3.32
  • Brexpiprazole 2 and 3 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.0083 · Ratio of response rate: 1.56 · 95% CI 1.10 to 2.22
  • Brexpiprazole 2 and 3 mg vs Placebo · Cochran-Mantel-Haenszel · p = <.0001 · Ratio of response rate: 1.85 · 95% CI 1.32 to 2.58
  • Brexpiprazole 2 and 3 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.0005 · Ratio of response rate: 1.57 · 95% CI 1.18 to 2.09
  • Brexpiprazole 2 and 3 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.0160 · Ratio of response rate: 1.32 · 95% CI 1.03 to 1.69

Adverse events

Collected over From signing of informed consent up to end of study (Week 16). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Brexpiprazole 2 mg0/75 (0%)0/73 (0%)5/73 (6.8%)
Brexpiprazole 3 mg1/153 (0.7%)6/153 (3.9%)10/153 (6.5%)
Placebo0/117 (0%)3/116 (2.6%)8/116 (6.9%)
Most frequent serious events
Showing 10 of 14
Most frequent serious events
EventBrexpiprazole 2 mgBrexpiprazole 3 mgPlacebo
Urinary tract infectionInfections and infestations0/732/1530/116
Hip fractureInjury, poisoning and procedural complications0/731/1531/116
Sars-Cov-2 test positiveInvestigations0/730/1531/116
Psychotic disorderPsychiatric disorders0/730/1531/116
Cardiac failureCardiac disorders0/731/1530/116
Covid-19Infections and infestations0/731/1530/116
PneumoniaInfections and infestations0/731/1530/116
FallInjury, poisoning and procedural complications0/731/1530/116
CachexiaMetabolism and nutrition disorders0/731/1530/116
DehydrationMetabolism and nutrition disorders0/731/1530/116
Most frequent other events
Most frequent other events
EventBrexpiprazole 2 mgBrexpiprazole 3 mgPlacebo
HeadacheNervous system disorders5/7310/1538/116

Baseline characteristics

Randomized Sample consisted of all participants who were randomized into this trial.

Age, Continuous
Age, Continuous(years)Brexpiprazole 2 mgBrexpiprazole 3 mgPlaceboTotal
Mean74.3 ± 7.374.6 ± 8.073.0 ± 7.074.0 ± 7.5
Sex: Female, Male
Sex: Female, Male(Participants)Brexpiprazole 2 mgBrexpiprazole 3 mgPlaceboTotal
Female439260195
Male326157150
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Brexpiprazole 2 mgBrexpiprazole 3 mgPlaceboTotal
Hispanic or Latino254637108
Not Hispanic or Latino5010780237
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Brexpiprazole 2 mgBrexpiprazole 3 mgPlaceboTotal
American Indian or Alaska Native0000
Asian0314
Native Hawaiian or Other Pacific Islander0000
Black or African American56112
White70144115329
More than one race0000
Unknown or Not Reported0000
Cohen-Mansfield Agitation Inventory (CMAI) Total Score
Cohen-Mansfield Agitation Inventory (CMAI) Total Score(score on a scale)Brexpiprazole 2 mgBrexpiprazole 3 mgPlaceboTotal
Mean78.6 ± 15.581.2 ± 17.279.4 ± 17.680 ± 17
08

Study locations

1 site
  • For additional information regarding sites, contact 844-687-8522
    Los Angeles, California 90036, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymized Individual participant data (IPD) that underlie the results of this study will be shared with researchers to achieve aims pre-specified in a methodologically sound research proposal. Small studies with less than 25 participants are excluded from data sharing.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data will be available after marketing approval in global markets, or beginning 1-3 years following article publication. There is no end date to the availability of the data.

Access criteria: Otsuka will share data on the Vivli data sharing platform which can be found here: https://vivli.org/ourmember/Otsuka/

Data sharing details ↗ · clinical-trials.otsuka.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2018 to primary completion in May 2022, 48 months.

Results were first posted in Sep 2023, 1 year 3 months after primary completion.

Of 75 industry-sponsored phase 3 interventional studies under Alzheimer Disease, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 61. This study's 48 months is above that.

Counting every sponsor, half of 101 studies reached it within 47 months; a quarter within 28 and three quarters within 73.

How these figures are worked out, and which studies are left out of them.

Registered
May 7, 2018
First posted
Jun 7, 2018
StartActual
May 16, 2018
Primary completionActual
May 23, 2022
CompletionActual
Jun 1, 2022
Results first posted
Sep 18, 2023
Last update
Sep 18, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 18, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03548584
Collaborators
H. Lundbeck A/S
Responsible party
Sponsor
First posted
Jun 7, 2018
Start date
May 16, 2018
Primary completion
May 23, 2022
Completion
Jun 1, 2022
Results posted
Sep 18, 2023
Last update
Sep 18, 2023

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Brexpiprazole

Start the discussion